Clone:
REA985
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, MICS, IF, IHC, MC
Alternative names:
PDCD1LG2, B7-DC, Btdc, CD273, PD-L2, PDCD1L2, PDL2

Extended validation for CD273 (PD-L2) Antibody, anti-human, REAfinity™

Specificity

Epitope competition
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Other clonesOverlap in epitope recognition with REA985
MIH18++
24F10C12-
TY25-
Cells were incubated with an excess of purified unconjugated CD273 (PD-L2) (REA985) antibody followed by staining with fluorochrome-conjugated antibodies of other known clones against the same marker. Based on the fluorescence signal obtained, the clones were identified as recognizing completely overlapping (++), partially overlapping (+), or completely different epitopes (-) of the marker.

Sensitivity

Performance comparison
Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.
View details
Flow cytometric comparison of different clones for CD273 (PD-L2). Mature MoDc cells were stained with CD273 (PD-L2) antibodies and with a suitable counterstaining. As a control, CD273 (PD-L2) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD273 (PD-L2). Mature MoDc cells were stained with CD273 (PD-L2) antibodies and with a suitable counterstaining. As a control, CD273 (PD-L2) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD273 (PD-L2). Mature MoDc cells were stained with CD273 (PD-L2) antibodies and with a suitable counterstaining. As a control, CD273 (PD-L2) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD273 (PD-L2). Mature MoDc cells were stained with CD273 (PD-L2) antibodies and with a suitable counterstaining. As a control, CD273 (PD-L2) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD273 (PD-L2). Mature MoDc cells were stained with CD273 (PD-L2) antibodies and with a suitable counterstaining. As a control, CD273 (PD-L2) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Flow cytometric comparison of different clones for CD273 (PD-L2). Mature MoDc cells were stained with CD273 (PD-L2) antibodies and with a suitable counterstaining. As a control, CD273 (PD-L2) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Fixation data
To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.
No fixation
Post fixation
View details
Comparison of staining pattern on non-fixed and fixed cells using CD273 (PD-L2) (REA985). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
View details
Comparison of staining pattern on non-fixed and fixed cells using CD273 (PD-L2) (REA985). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
Comparison of staining pattern on non-fixed and fixed cells using CD273 (PD-L2) (REA985). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD273 (PD-L2) Antibody, anti-human, REAfinity™

Overview

Clone REA985 recognizes the human CD273 antigen, also known as B7-DC or PD-L2. CD273 with an approximate molecular weight of 29 kDa is a type I transmembrane protein, belonging to the B7 family of protein ligands and to the Ig superfamily. CD273 is mainly expressed on dendritic cells (DCs) and activated macrophages. It has been shown to interact with programmed-death-receptor 1 (PD-1). A stimulatory as well as a inhibitory role of CD273 in T cell activation has been proposed.
Additional information: Clone REA985 displays negligible binding to Fc receptors.

Alternative names

PDCD1LG2, B7-DC, Btdc, CD273, PD-L2, PDCD1L2, PDL2

Detailed product information

Technical specifications

CloneREA985
Clonalitymonoclonal
Isotyperecombinant human IgG1
Isotype controlREA Control Antibody (S), human IgG1
Hosthuman cell line
Type of antibodyPrimary antibodies, Recombinant antibodies
Specieshuman
AntigenCD273 (PD-L2)
Alternative names of antigenPDCD1LG2, B7-DC, Btdc, CD273, PD-L2, PDCD1L2, PDL2
Molecular mass of antigen [kDa]29
Distribution of antigendendritic cells, macrophages
Entrez Gene ID80380
RRIDAB_2727605, AB_2727651, AB_2727606, AB_2727652, AB_2727607, AB_2727656, AB_2727611, AB_2727653, AB_2727608, AB_2727654, AB_2727609, AB_2727655, AB_2727610, AB_2801925, AB_2727650

Resources for CD273 (PD-L2) Antibody, anti-human, REAfinity™

Certificates

Please follow this
link
to search for Certificates of Analysis (CoA) by lot number.

References for CD273 (PD-L2) Antibody, anti-human, REAfinity™

Publications

  1. Tseng, S. Y. et al. (2001)
    B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells.
    J. Exp. Med. 193: 839-846
  2. Greenwald, R. J. et al. (2005) The B7 family revisited. Annu. Rev. Immunol. 23: 515-548
  3. Pfistershammer, K. et al. (2006) No evidence for dualism in function and receptors: PD-L2/B7-DC is an inhibitory regulator of human T cell activation. Eur. J. Immunol. 36(5): 1104-1113

Related products for
CD273 (PD-L2) Antibody, anti-human, REAfinity™

3 products available

Seems like you are coming from USA!
Do you want to visit our website in your country?